Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors

Brain Research

Volumn 894, Issue 2, 2001, Pages 167-180

  Miyamoto, Seiya ^a   Mailman, Richard B ^a   Lieberman, Jeffrey A ^a   Duncan, Gary E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

D1 like dopamine receptor; D1A knockout mice; Ketamine; N Methyl D aspartate antagonist; SCH23390; Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DEOXYGLUCOSE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HIPPOCAMPUS; KNOCKOUT MOUSE; LIMBIC CORTEX; METABOLIC ACTIVATION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANESTHETICS, DISSOCIATIVE; ANIMALS; ANTIMETABOLITES; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; DEOXYGLUCOSE; DOPAMINE ANTAGONISTS; FEMALE; KETAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0035896404     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)01991-6     Document Type: Article

References (92)

1. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
2. The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats
3. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
4. 1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
5. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors
6. Effects of NMDA antagonism on striatal dopamine release in healthy subjects - Application of a novel PET approach
7. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
8. 1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys
9. 1 receptor stimulation
10. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated
11. 1A dopamine receptor: Paradoxical elevation of grooming syntax
12. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
13. The glutamatergic dysfunction hypothesis for schizophrenia
14. 1A-deficient mouse
15. 1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
16. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action
17. Altered striatal function in a mutant mouse lacking D1A dopamine receptors
18. 1 dopamine receptor-deficient mouse: Cocaine-induced regulation of immediate-early gene and substance P expression in the striatum
19. High resolution autoradiographic imaging of brain activity patterns with 2-deoxyglucose: Regional topographic and cellular analysis
20. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
21. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: Support for NMDA receptor involvement in responses to subanesthetic dose of ketamine
22. Comparison of the effects of clozapine, risperidone, and lanzapine on ketamine-induced alterations in regional brain metabolism
23. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia
24. An integrated view of pathophysiological models of schizophrenia
25. High-resolution autoradiographic imaging of brain activity patterns with radiolabeled 2-deoxyglucose and glucose
26. Brain activity patterns: Assessment by high resolution autoradiographic imaging of radiolabeled 2-deoxyglucose and glucose uptake
27. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
28. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula
29. 1 agonist containing a rigid-beta-phenyldopamine pharmacophore
30. 1 receptor in the cognitive symptoms of schizophrenia
31. 1 receptors in prefrontal cells and circuits
32. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice
33. Recent advances in the phencyclidine model of schizophrenia
34. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients
35. Extension of multiple range tests to group means with unequal numbers of replications
36. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
37. Molecular characteristics of mammalian dopamine receptors
38. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
39. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
40. 2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice
41. 3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride
42. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices
43. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
44. NMDA receptor function and human cognition - The effects of ketamine in healthy volunteers
45. On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801
46. The distribution of alterations in energy metabolism in the rat brain produced by apomorphine
47. Influence of dopaminergic systems on the lateral habenular nucleus of the rat
48. Serotonergic component of SCH 23390: In vitro and in vivo binding analyses
49. Dopamine-N-methyl-D-aspartate interactions in the modulation of locomotor activity and memory consolidation in mice
50. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity
51. 1 receptor deficient mice
52. Developing novel antipsychotic drugs: Strategies and goals
53. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice
54. Activation of glutamatergic neurotransmission by ketamine - A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
55. Reversal of phencyclidine effects by a group II metabotrophic glutamate receptor agonist in rats
56. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: Differential action on firing pattern related to anatomical localization
57. 1 agonist C-APB in mice
58. 1 receptors in schizophrenia revealed by PET
59. Glutamate receptor dysfunction and schizophrenia
60. 1, modify brain glucose metabolism
61. 2 antagonist sulpiride on glucose utilization in dopaminergic regions of rat brain
62. Haloperidol and cerebral metabolism in the conscious rat: Relation to pharmacokinetics
63. Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats
64. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo
65. Induction patterns of neuroleptic-induced Fos-like immunoreactivity as predictors of atypical antipsychotic activity
66. Regional effects of MK-801 on dopamine release effects of competitive NMDA or 5-HT2A receptor blockade
67. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys
68. 1-dopamine receptor function in schizophrenia
69. Acute cocaine administration: Effects on local cerebral blood flow and metabolic demand in the rat
70. Behavioural assessment of mice lacking D1A dopamine receptors
71. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and C-11-raclopride in normal human subjects
72. 3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release
73. Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects
74. 1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervation
75. Interaction between dopamine and glutamate receptors following treatment with NMDA receptor antagonists
76. Modulation of MK-801 response by dopaminergic agents in mice
77. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats modulation by dopamine
78. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
79. 18F] fluorodeoxyglucose (FDG)
80. 11C] raclopride PET study of a model psychosis in humans
81. Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain
82. 3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity
83. Effects of D- and L-amphetamine on local cerebral glucose utilization in the conscious rat
84. 1 receptors
85. 1 receptors in prefrontal cortex
86. 1 receptor mutant mice
87. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses
88. Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons
89. Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine